Flow cytometric analysis of Human CD200 expression on human PBMC (human peripheral blood mononuclear cell). Human PBMC (human peripheral blood mononuclear cell) were stained with Brilliant Violet 421™ Mouse Anti-Human CD19 Antibody and either Rabbit IgG Isotype Control (Left panel) or SDT FITC Rabbit Anti-Human CD200 Antibody (Right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
Host | Rabbit |
Antigen | CD200 |
Synonyms | OX-2 membrane glycoprotein; MOX1; MOX2 |
Immunogen | Recombinant Protein |
Location | Cell membrane |
Accession | P41217 |
Clone Number | S-1008-60 |
Antibody Type | Recombinant mAb |
Isotype | IgG |
Application | FCM |
Reactivity | Hu |
Positive Sample | human PBMC |
Purification | Protein A |
Concentration | 0.2 mg/ml |
Conjugation | FITC |
Physical Appearance | Liquid |
Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 5 μl per million cells in 100μl volume | Hu |
Background
CD200, also known as OX-2 membrane glycoprotein, is a type I transmembrane protein encoded by the CD200 gene and belongs to the immunoglobulin superfamily. It is primarily expressed on various cell types, including immune cells, neuronal cells, and some non-hematopoietic cells. CD200 plays a crucial role in immune regulation by interacting with its receptor, CD200R, which is mainly expressed on myeloid cells, microglia, and activated T cells. This interaction generates inhibitory signals that suppress immune responses, such as reducing the production of inflammatory cytokines like IL-2 and IFN-γ, and promoting the expansion of regulatory T cells. In addition, CD200 is involved in maintaining immune tolerance and preventing autoimmune diseases. However, its expression on tumor cells can lead to immune evasion by inhibiting antitumor T-cell responses. Therefore, CD200 is considered a potential target for cancer immunotherapy and the treatment of inflammatory and autoimmune diseases.
Picture
Picture
FC
